LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

Strona główna・Stock List・Pacific Biosciences of California Inc

Pacific Biosciences of California Inc

Closed

SectorHealthcare

1.57 6.08

Buy Sell

Overview

Share price change

24h

Current

Min

1.44

Max

1.6099999999999999

Key metrics
By Trading Economics
Income	32M -8.3M
Sales	-7.5M 37M
EPS	-0.12
Profit margin	-22.258
Employees	485
EBITDA	509K -38M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+59.73% upside

Dividends
By Dow Jones
Next Earnings	6 sie 2026

Market Stats
By TradingEconomics
Market Cap	-90M 391M
Previous open	-4.51
Previous close	1.57

News Sentiment

By Acuity

50%

153 / 344 Ranking in Healthcare

Pacific Biosciences of California Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

1 cze 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1 cze 2026, 23:38 UTC

Acquisitions, Mergers, Takeovers

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1 cze 2026, 23:37 UTC

Market Talk

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1 cze 2026, 23:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 cze 2026, 23:01 UTC

Market Talk

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1 cze 2026, 22:08 UTC

Acquisitions, Mergers, Takeovers

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 cze 2026, 22:01 UTC

Acquisitions, Mergers, Takeovers

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 cze 2026, 22:01 UTC

Acquisitions, Mergers, Takeovers

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1 cze 2026, 21:55 UTC

Acquisitions, Mergers, Takeovers

Greg Abel's Week Is Off to Quite a Start -- WSJ

1 cze 2026, 21:53 UTC

Market Talk

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1 cze 2026, 21:22 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1 cze 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

1 cze 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 cze 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

1 cze 2026, 20:46 UTC

Acquisitions, Mergers, Takeovers

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1 cze 2026, 20:22 UTC

Acquisitions, Mergers, Takeovers

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1 cze 2026, 20:21 UTC

Acquisitions, Mergers, Takeovers

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1 cze 2026, 20:21 UTC

Acquisitions, Mergers, Takeovers

Array Digital Infrastructure Declares $11 Special Div

1 cze 2026, 20:20 UTC

Acquisitions, Mergers, Takeovers

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1 cze 2026, 19:40 UTC

Market Talk

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1 cze 2026, 19:28 UTC

Market Talk

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1 cze 2026, 19:01 UTC

Market Talk

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1 cze 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1 cze 2026, 18:54 UTC

Acquisitions, Mergers, Takeovers

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1 cze 2026, 18:33 UTC

Market Talk

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1 cze 2026, 18:32 UTC

Market Talk

Precious Metals Fall to Start June -- Market Talk

1 cze 2026, 18:00 UTC

Acquisitions, Mergers, Takeovers

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1 cze 2026, 17:18 UTC

Market Talk

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1 cze 2026, 17:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 cze 2026, 17:10 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Peer Comparison

Price change

Pacific Biosciences of California Inc Forecast

Price Target

By TipRanks

59.73% upside

12 Months Forecast

Average 2.38 USD 59.73%

High 3 USD

Low 1.5 USD

Based on 4 Wall Street analysts offering 12 month price targets forPacific Biosciences of California Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Pacific Biosciences of California Inc - Dist in the past 3 months.

Sentiment

By Acuity

153 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.